<i>e-lgp</i> curve of improved red clay. حسب Quan Shen (37564)

الموضوعات:

Soil partice-size distribution. حسب Yonggang Huang (223155)

الموضوعات:

Group-based descriptive statistics and effect sizes. حسب Murat Tutar (22250461)

الموضوعات:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. حسب Francesca Catto (21253435)

"…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …"

Comparison of the Non-healed but Improved DUs Based on Initial Wound Area Size in 2022 vs. 2023. حسب Heba Tallah Mohammed (2822432)

الموضوعات:

Comparison of the Non-healed but Improved PIs Based on Initial Wound Area Size in 2022 vs. 2023. حسب Heba Tallah Mohammed (2822432)

الموضوعات:

JP4-039 decreases mitochondrial ROS in human coronary artery endothelial cells <i>in vitro.</i> حسب Rayane Brinck Teixeira (6676529)

Enrichment analysis of genes from the significant MS module. حسب Lai Jiang (2401513)

الموضوعات:

Transition probabilities and class sizes for three-step LTA model (N = 432). حسب Carolin Oetzmann (11397968)

الموضوعات:

Particle size distribution curve. حسب Quan Shen (37564)

الموضوعات:

Based on our time series data(first from the left), the visualizations of linear residual predictions under different decimation rates (next three) show that as the decimation rate... حسب Hua Huo (1818133)

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. حسب Xiang-Fan Chen (13932983)

Brain regions with significantly decreased activations for the Raven task are shown in blue. حسب Morteza Fattahi (15892028)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg حسب Ling Kui (6108440)

"…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …"